🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bristol
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Bristol

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca23 Eli Lilly and Company18 Merck Sharp & Dohme LLC17 Boehringer Ingelheim10 Janssen Research & Development, LLC9
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
269 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Eisai Inc.
Phase 3
1,400
Bristol, Glasgow, London
2020-07-14
Active, closed
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
419
Birmingham, Bristol, Cardiff, London, Manchester, Newcastle upon Tyne
2020-06-12
Active, closed
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
NCT04404660Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Autolus Limited
Phase 1/2
153
Cambridge, London, Manchester, Glasgow, Newcastle upon Tyne, Birmingham, Bristol
2020-06-03
Active, closed
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
818
Aberdeen, Bournemouth, Bristol, Cardiff, Cheltenham, London, Manchester, Sutton
2020-04-16
Active, closed
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT04088396Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company
Phase 3
58
Bristol, Liverpool, London, Oxford, Sheffield
2020-02-12
Active, closed
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
NCT03972488Gastro-enteropancreatic Neuroendocrine Tumor
Advanced Accelerator Applications
Phase 3
226
Bristol, London, Sheffield
2020-01-08
Recruiting
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
Abbott Medical Devices
Observational
1,000
Liverpool, Bristol, Glasgow, London
2019-11-26
Active, closed
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
NCT04088409Uveitis
Eli Lilly and Company
Phase 3
30
Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield
2019-10-16
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
CellCentric Ltd.
Phase 1/2
250
Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester
2019-08-09
Active, closed
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
2,517
Bristol, Cardiff, Dundee, London, Preston, Sutton, Wakefield, Wolverhampton
2019-06-11
Active, closed
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3
415
Plymouth, Bristol, Cardiff, Edinburgh, Glasgow, London, Manchester
2019-06-04
Active, closed
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
NCT04053803Sickle Cell Disease
Imara, Inc.
Phase 2
30
Bristol, London
2019-05-22
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
AstraZeneca
Phase 3
810
Bristol, Cambridge, London, Manchester, Oxford, Romford, Sheffield
2019-04-16
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
Eli Lilly and Company
Phase 3
190
Bristol, Liverpool, London, Oxford, Sheffield
2019-04-05
Recruiting
Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator
NCT03876054Chronic Pain
Abbott Medical Devices
Observational
2,000
Norwich, Liverpool, Bristol, Leeds
2019-03-13
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,240
Bristol, Nottingham, Colchester, London, Solihull, Truro
2018-12-27
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
507
Bristol, Cardiff, London
2018-11-28
Active, closed
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
NCT03690388Differentiated Thyroid Cancer
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche
Phase 3
1,000
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2018-09-20
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791Hepatocellular Carcinoma
Exelixis
Phase 3
837
Bristol, Cambridge, London, Manchester, Belfast
2018-06-10
Active, closed
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
pharmaand GmbH
Phase 3
1,097
Canterbury, Cliftonville, Brighton, Bristol, Cambridge, Edinburgh, Lancaster, Leeds
2018-05-14
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Airdrie, Bristol, Cardiff, London, Oxford
2018-05-03
Active, closed
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922Melanoma
Bristol-Myers Squibb
Phase 2/3
714
Bristol, Glasgow, Swansea, London, Inverness
2018-04-11
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Active, closed
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847Metastatic Triple Negative Breast Cancer
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Rows per page Showing 226–250 of 269
Previous 8 9 10 11 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/bristol

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.